15 / 164
275
[ASMA SEVERA EN ADULTOS: ENFOQUE DIAGNÓSTICO Y TRATAMIENTO - Dra. Paulina Barría P. y cols.]
11. Baines KJ, Simpson JL, Wood LG et al. Transcriptional phenotypes
of asthma defined by gene expression profiling of induced
sputum samples. J Allergy Clin Immunol 2011;127:153-60.
12. Zhang Q, Illing R, Hui CK, et al. Bacteria in sputum of stable
severe asthma and increased airway wall thickness. Respir Res
2012;13:35.
13. Fitzpatrick AM, Holgin F, Teague WG, et al. Alveolar macrophage
phagocytosis is impaired in children with poorly controlled
asthma. J Allergy clin Immunol 2008; 121:1372-78.
14. Brusselle GG, Joos G. Is there a role for macrolides in severe
asthma? Curr Opin Pulm Med. 2014 Jan;20(1):95-102.
15. Gupta S, Raj V, Castro M et al. Imaging in severe asthma.
Capitulo 12. European Respiratory Monograph 51: Difficult-To-
Treat Severe Asthma.
16. Dykewicz MS. Occupational asthma: current concepts in
pathogenesis, diagnosis, and management. J Allergy Clin
Immunol. 2009;123(3):519.
17. Salinas M, Rojas S, Abarca G et al. 2007. Asma Ocupacional en
la Asociación Chilena de Seguridad 1990 a 2006. Cienc Trab,
Ene- Mar: 9 (23): 18-22.
18. Bourdin A, Halimi L, Vachier I, et al. Adherence in severe asthma.
Clin Exp Allergy. 2012 Nov;42(11):1566-74.
19. ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent
exacerbations in difficult-to-treat asthma. Eur Respir J. 2005
Nov;26(5):812-8.
20. Dixon AE, Holguin F, Sood A, et al. An Official American Thoracic
Society Workshop Report: Obesity and Asthma. Proc Am Thorac
Soc Vol 7. pp 325–335, 2010.
21. Wenzel S. Asthma phenotypes: the evolution from clinical to
molecular approaches. Nat Med. 2012 May 4;18(5):716-25.
22. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma
phenotypes using cluster analysis in the Severe Asthma Research
Program. Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-
23.
23. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical
asthma phenotypes. Am J Respir Crit Care Med. 2008 Aug
1;178(3):218-24.
24. Siroux V, Basagaña X, Boudier A, et al. Identifying adult asthma
phenotypes using a clustering approach. Eur Respir J. 2011
Aug;38(2):310-7.
25. Chung KF. New treatments for severe treatment-resistant
asthma: targeting the right patient. Lancet Respir Med 2013;
1:639-52.
26. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly
controlled with standard combination therapy. N Engl J Med.
2012;367(13):1198.
27. Martin RJ, Szefler SJ, King TS, et al. The predicting response
to inhaled corticosteroid efficacy (PRICE) trial. J Allergy Clin
Immunol 2007; 119:73–80.
28. Ayres JG, Bateman ED, Lundbäck B, et al. High dose fluticasone
propionate, 1 mg daily, versus fluticasone propionate, 2 mg
daily, or budesonide, 1.6 mg daily, in patients with chronic severe
asthma. International Study Group. Eur Respir J. 1995;8(4):579.
29. Hew M, Chung KF. Corticosteroid insensitivity in severe
asthma: significance, mechanisms and aetiology. Intern Med J
2010;40:323–34.
30. Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of
omalizumab in allergic asthma: an analysis of biomarkers in the
EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804.
31. Rodrigo GJ1, Neffen H, Castro-Rodriguez JA. Efficacy and safety
of subcutaneous omalizumab vs placebo as add-on therapy to
corticosteroids for children and adults with asthma: a systematic
review. Chest. 2011 Jan;139(1):28-35.
32. Castro, M., Rubin, A., Laviolette, et al. AIR2 Trial Study Group.
Effectiveness and safety of bronchial thermoplasty in the
treatment of severe asthma: a multicenter randomized, double-
blind, sham-controlled clinical trial. Am J Respir Crit Care Med
2010;181: 116–124.
33. Torrego A, Solà I, Munoz AM, et al. Bronchial thermoplasty for
moderate or severe persistent asthma in adults. Cochrane
Database Syst Rev.2014;3:CD009910.
34. Rogers L, Reibman J. Stepping down asthma treatment. Curr
Opin Pulm Med. 2012;18(1):70-75.
35. Banh HL. Unconventional Treatment Options in Severe Asthma:
An Overview. J Pharm Pharmaceut Sci 14(3) 387 - 399, 2011.
36. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe
eosinophilic asthma (DREAM): a multicentre, double-blind,
placebo- controlled trial. Lancet 2012; 380: 651–59.
37. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in Persistent
Asthma with Elevated Eosinophil Levels. N Engl J Med 2013;
368:2455-2466.
38. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-
blind, placebo-controlled study of tumor necrosis factor-alpha
blockade in severe persistent asthma. Am J Respir Crit Care Med.
2009;179(7):549.
39. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin
for prevention of exacerbations in severe asthma (AZISAST): a
multicentre randomised double-blind placebo-controlled trial.
Thorax 2013; 68: 322–29.
40. Fajt M, Wenzel S. Biologic therapy in asthma: entering the new age
of personalized medicine. J Asthma. 2014 Sep;51(7):669-76.